

PRAXAIR INC
Form 425
August 31, 2017

Filed by Linde AG
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934

Subject Companies:
Praxair, Inc.
(Commission File No.: 001-11037)
Linde AG

Commission File No. for Registration
Statement on Form S-4: 333-218485

August 31, 2017

Linde and Praxair: A Compelling Combination August 31, 2017

1 2016 pro forma sales without adjustment for potential divestitures and regulatory limitations Linde and Praxair: A Compelling Combination Leverages unique strengths of each company to create a global industrial gas leaderLinde's engineering & technology and Praxair's operational excellenceEstablishes strong positions in all key geographies and end-marketsMore balanced and diverse global portfolioIncreases exposure to long term macro growth trendsHealthcare, emerging markets, clean energy, digitalization Considerable value through ~\$1.2 B in annual cost & capex synergies and efficienciesStrong balance sheet and cash flow with financial flexibility to invest in future growth Combined pro-forma revenue of ~\$29 B1 and current market value of over \$73 B Strategic Financial 2

Edgar Filing: PRAXAIR INC - Form 425

Creating A Global Industrial Gas Leader... 1 Sales based on 2016 public filings. Air Liquide includes 12 months of Airgas acquisition and related divestments. Air Products excludes Materials Technologies2 2016 pro forma sales without adjustment for potential divestitures and regulatory limitations3 Others: includes independents* Source: Gasworld Captive: customer owned
plant 22 8 25* 38* Others3 29 Captive Industrial Gas Landscape1 (\$ B) Sales By
Geography2 Other~\$3 B Americas~\$12 B EMEA~\$8 B Asia/Pacific~\$6 B ... Across a much broader global
footprint 3

Edgar Filing: PRAXAIR INC - Form 425

Leverages Complementary Strengths... Product Lines End-Markets Geographies Core Competencies •
Engineering & Technology EMEAAsia/Pacific HyCOLarge ASUs Chemicals & Energy– H2, LNG, CCS,
EORHealthcare Petrochemicals– US Gulf CoastMetals Standardized ASUsNon-cryo Operational
excellence North AmericaSouth America 4 ...Which are unique and proven with long-standing leadership ASU –
Air separation unit(s) HyCo – Syngas plantsCCS – Carbon capture storage LNG – Liquefied natural gas EOR – enhanced
oil recovery

Edgar Filing: PRAXAIR INC - Form 425

Establishes A More Balanced Portfolio... ...With strong positions in key geographies and end-markets 1 Based on
 2016 public filings and pro forma sales without adjustment for potential divestitures and regulatory limitations.2
 Includes cylinder and other services Geography1 End-Markets1 Supply Model Americas
 EMEAAsia/Pacific Other On-site Bulk Cylinder2 Other Chemicals & Energy Manufacturing
 HealthcareMetals & Glass Food & Beverage Electronics
 Other 43% 26% 21% 10% 19% 18% 17% 13% 7%7% 19% 25% 5 28% 37% 10%

Edgar Filing: PRAXAIR INC - Form 425

Combination Would Yield ~ \$1.2 B Synergies & Efficiencies... Time to achieve ~ 3 years after closing
Cost to implement ~ \$1.0 B Corporate right-sizing Operational optimization Includes existing cost reduction
programs Productivity Procurement Cost Synergies & Efficiencies 1~ \$1.0 B 1 Based on 2016 financials of Linde
and Praxair. Synergies and cost efficiencies have been adjusted for potential divestitures. Efficient asset
utilization Procurement Maintenance capex optimization Capex Synergies 1~ \$0.2 B Cost Synergies &
Efficiencies 1~ \$1.2 B Capex ~ \$0.2 B Cost ~ \$1.0 B SG&A COGS Supply Chain / Other Growth
Synergies ++ B 6

Edgar Filing: PRAXAIR INC - Form 425

...And Create Value For All Stakeholders Deep & innovative product offerings Broader end-market
applications Cost efficient solutions Shared values... safety, integrity, community Employer of choice Environmental
stewardship Higher cash flow & stronger balance sheet Greater flexibility to invest in future growth Increased
shareholder distributions Comprehensive products & services Wider global reach / accelerated deployment Further
enhanced supply reliability Stronger Enterprise For All Stakeholders Enhanced Technology
Capability Superior Customer Offerings More Sustainable Enterprise Stronger Financials 7

Edgar Filing: PRAXAIR INC - Form 425

Strong Balance Sheet and Cash Flow Greater flexibility for growth investments and shareholder distributions 1
 Based on Linde and Praxair's consolidated financial statements combined for pro forma purposes. See appendix2
 Non-GAAP and non-IFRS measure. See Appendix for reconciliation3 Excluding savings attributable to divestitures
 and estimated one-time cost of approximately \$1.0B (including approximately \$0.2B of estimated transaction costs) to
 achieve these savings. Operating cash flow of\$0.7B represents the \$1.0B of Adj. EBITDA savings after taking into
 account the assumed pro forma effective tax rate4 Illustrates the full run-rate targeted savings based on combined
 2016 results. Excludes any potential divestitures and regulatory limitations and assumes all other items including pro
 forma effective tax rate remains unchanged. Not indicative of future results of combined business; provided as
 illustrative example only \$28.7\$9.0 31.5% \$6.8 (\$3.2) \$3.6 2.1 1.9 SalesAdj. EBITDA2Adj. EBITDA
 Margin2 Operating Cash Flow Capex Free Cash Flow2 Net Debt/Adj. EBITDA2 Combined1 Total4 \$28.7\$8.0
 28.1% \$6.1(\$3.4) \$2.7 Targeted Savings3 \$1.0 \$0.7\$0.2 \$0.9 2016 Financials (\$ B) 8

Integration and Execution 9 Established integration frameworkJoint integration committee with executive oversightSynergy targets alignedAgreed-upon prioritiesLay the foundation for the new companyGuiding principles: one team, one vision, one operating model, shared valuesPerformance-driven cultureMinimal distraction for vast majority of people and operationsHomogenous products with local management structures Preparing for a successful integration

Edgar Filing: PRAXAIR INC - Form 425

Regulatory Review and On-going Integration Planning Key Next Steps and
Timeline Board approvals / BCA signed Start of tender period for the German Exchange
Offer Praxair special shareholder meeting Regulatory approval / expected closing Jun 1 2017 Aug 15 2017 Sept
27 2017 H2 2018 End of German Exchange Offer acceptance period Oct 24 2017 10 1 Record date: 08 Aug
2017

Praxair Special Shareholder Meeting Voting Items 11 The Praxair Board of Directors unanimously recommends that Praxair shareholders vote:(1) “FOR” the business combination proposal; “FOR” the non-binding advisory distributable reserves creation proposal;Under Irish law, dividends may be paid (and share repurchases must generally be funded) only out of so called “distributable reserves”Distributable reserves generally means the accumulated realized profits of Linde plc less accumulated realized losses of Lindeplc and includes reserves created by way of capital reductions“FOR” the non-binding advisory executive compensation proposal; andCompensation that may become payable to Praxair’s named executive officers in connection with the business combination (4) “FOR” the special shareholder meeting adjournment/postponement proposal

Reasons to Tender Linde AG Shares as Soon as Possible 12 In the German exchange offer, Linde plc has established a minimum acceptance threshold of 75%, which needs to be reached by 24 October 2017, to consummate the transaction. If the 75% threshold is not reached, the deal may fail. Reasons to tender early: Significant portion of Linde shares are held by passively managed funds that can only tender their shares after certain thresholds have been reached; achieving these thresholds early provides sufficient time for passively managed funds to tender. For certain exchange traded options (e.g. EUREX), the underlying will only be swapped to the tendered line after certain thresholds have been reached. Provides Linde plc and the market with better visibility on the overall development of the tender. Increases prominence of tendered share versus ordinary share to help alleviate market concerns regarding liquidity.

Edgar Filing: PRAXAIR INC - Form 425

Antitrust Filings Update 13 The business combination is subject to review by antitrust authorities in approximately 24 jurisdictions:European Union: Parties engaged in pre-notification phase with the EU CommissionUnited States: Notifications were filed by Linde AG and Praxair in July 2017 with the FTC. Each company received a second request in August from the FTC and responses are in progress.China, India and South Korea: Notifications submitted in mid-August 2017Brazil, Canada, Mexico and Russia: Formal filings intended to be made in mid-Sept. 2017In addition, antitrust filings are being made in other jurisdictions

Appendix 14

Edgar Filing: PRAXAIR INC - Form 425

Ways for Linde AG Shareholders to Support the Transaction 15 Tender Linde AG shares as soon as possible Linde AG shareholders that have tendered should proactively confirm this to Linde plc As the acceptance process via the custodian banks is on a “no name” basis, Linde plc consequently has no visibility as to which shareholders have tendered their shares If investors proactively confirm the tendering of their shares, Linde plc and the market will benefit from the additional visibility Please email the confirmation of having tendered your shares to investorrelations@linde.com or by fax to +49 (89) 35757-1398, ideally with the below statement: I hereby confirm that [Shareholder] has tendered the Linde Aktiengesellschaft shares that it [holds or manages and controls] in the exchange offer by Linde plc. [Shareholder] hereby consents to disclosure of the foregoing by Linde Aktiengesellschaft, Linde plc and their affiliates. [Signed], [Name], [Title]

Edgar Filing: PRAXAIR INC - Form 425

Key Terms Of The Combination Governance Equal representation from Linde and Praxair on Linde plc's Board of Directors Wolfgang Reitzle, Chairman of the Board Stephen Angel, CEO and Director Organization CEO based in Danbury, CT Corporate functions appropriately split between Danbury, CT and Munich, Germany Incorporation & Name Linde plc incorporated in Ireland - a neutral European Economic Area (EEA) country Retain Linde's name globally Structure All-stock merger transaction Linde shareholders to receive 1.540 shares in Linde plc for each Linde AG share exchanged Praxair shareholders to receive one share in Linde plc for each Praxair share Linde and Praxair shareholders each own approximately 50% of Linde plc - Assumes 100% of Linde shareholders tender into the exchange offer Stock Exchanges & Credit Rating Linde plc listed on and tradable on the New York and Frankfurt Stock Exchanges Seek inclusion in key indices (S&P 500 & DAX 30) Commitment to a strong investment grade credit rating

16

Edgar Filing: PRAXAIR INC - Form 425

High Profile Linde plc Board (1/3) 17 Name Age Biographical Information Prof. Dr. Wolfgang Reitzle Chairman 68 Former President and Chief Executive Officer of Linde AG and Chairman of the Supervisory Board of Linde since 2016;– Chairman of the Mediation, Standing and Nomination Committees Current Chairman of the Supervisory Board of Continental and Medical Park, a member of the Supervisory Board of Axel Springer and Ivoclar Vivadent Stephen F. Angel CEO 61 Chairman and CEO of Praxair since 2007 Director at PPG Industries, where he serves on the Officers-Directors Compensation Committee and is the Chairman of the Technology and Environment Committee Director at the U.S.-China Business Council Prof. DDr. Ann-Kristin Achleitner 51 Member of the Supervisory Board of Linde since 2011 Professor at TU Munich, Chair of Entrepreneurial Finance Member of the Supervisory Board of Deutsche Börse and Munich Re and a director at ENGIE Dr. Clemens Börsig 69 Member of the Supervisory Board of Linde since 2006– Chairman of the Audit Committee Member of the Supervisory Board of Daimler, a director at Emerson Electric Company and Chairman of the Board of Directors of the Deutsche Bank Foundation

Edgar Filing: PRAXAIR INC - Form 425

High Profile Linde plc Board (2/3)

| 18 | Name | Age | Biographical Information |
|----|--|-----|---|
| | Dr. Nance K. Dicciani | 69 | Director at Praxair since 2008– Chairperson of the Technology, Safety and Sustainability Committee |
| | Director at AgroFresh Solutions, LyondellBasell Industries and Halliburton | | Dr. Thomas Enders |
| | 58 | | Member of the Supervisory Board of Linde since 2017 |
| | | | CEO of Airbus since 2012 |
| | | | Chairman of the Supervisory Board of Airbus Defence and Space and President of Airbus SAS |
| | Franz Fehrenbach | 68 | Member and Second Deputy Chairman of the Supervisory Board of Linde since 2013 and 2017, respectively |
| | | | Chairman of the Supervisory Board of Bosch, Deputy Chairman of the Supervisory Board of STIHL and a member of the Supervisory Board of BASF |
| | Edward G. Galante | 66 | Director at Praxair since 2007– Chairman of the Compensation & Management Development Committee |
| | | | Lead Independent Director at Celanese and a director at Tesoro and Clean Harbors |

Edgar Filing: PRAXAIR INC - Form 425

High Profile Linde plc Board (3/3) 19 Name Age Biographical Information Larry D. McVay 69 Director at Praxair since 2008– Chairman of the Finance & Pension CommitteePrincipal of Edgewater Energy and retired Chief Operating Officer of TNK- BP HoldingDirector at Chicago Bridge & Iron Company and Callon Petroleum Company Dr. Victoria Ossadnik 49 Member of the Supervisory Board of Linde since 2016Vice President Enterprise Services Delivery at Microsoft Deutschland Martin H. Richenhagen 65 Director at Praxair since 2015President and CEO of AGCO since 2004 and Chairman of the Board of Directors of AGCO since 2006Director at PPG Industries Robert L. Wood 63 Director at Praxair since 2004, Lead Director since 2013– Chairman of the Governance & Nominating CommitteeDirector at Univar and MRC Global

Shared History and Heritage

Acquired Yara CO2 Acquired US based

NuCO2Acquired Messer’s Germany businessAcquired Liquid CarbonicFormation of Praxair – spun off Linde division
from UCCLinde Homecare Medical Systems formed in UCC; Sale of Linde’s Homecare business as Lincare
Formation of Union Carbide (UCC); UCC takes over Linde's US business CCAarrll LLIinnddee ffouunndss
““GGeesseellllscchhaafftt ffüürr LLIinnddee””ss EEiissmmaasschhiinneenn”” iinn WWiieessbbaaddeennCCAarrll
LLiinnddee ssuuccceessssffuullly lliiquueefffiess aattmmoossppheerriicc aaiirr;; aanndd rreeceeiiveess aa
ppaatteenttLLiinnddee AAirri PPrroodduucttss ffoormmeedd iinn UUSSLinde Air Products sold to Union
CarbideRReeggaainni eedd rriigghhttss ttoo tthee nnaamnee ““LLiinnddee”” iinn tthee UUS Acquired Swedish gas
company AGAAcquired UK based BOC GroupAcquired US based
Lincare 1879 20 18751895 1907 1917 1999 2000 2006 2012
2013 1992 2016 1995 2004 19721987 Linde Praxair Linde Praxair Merge

21 Non-GAAP Reconciliations (1) Based on Linde and Praxair's consolidated financial statements combined for pro forma purposes including estimated income adjustments for US GAAP and purchase accounting. Linde's amounts translated using the EUR/USD exchange rates: Statement and Cash Flow (1.1069) and Balance Sheet (1.0517).(2) Combined free cash flow is calculated as follows (\$ M): * Reflects an adjustment related to interest payments, which are classified as a financing activity under IFRS and as an operating activity under US GAAP.(3) Net debt includes total debt less cash and cash equivalents and securities as reported in Linde and Praxair's consolidated financial statements. Adjusted EBITDA, Adjusted EBITDA Margin(1) Combined (\$ M) Net income from continuing operations(including noncontrolling interests) 2,623 Add: cost reduction program and other charges (pre-tax) 224 Add: interest expense - net (including bond redemption) 390 Add: income taxes 865 Add: depreciation and amortization 3,944 Adjusted EBITDA 8,046 Sales 28,682 Adjusted EBITDA MarginFree Cash Flow(2) 28.1% Operating cash flow 6,152 Less: capital expenditures (3,414) Free Cash FlowDebt-To-Adjusted EBITDA Ratio(3) 2,738 Beginning net debt 17,546 First quarter ending net debt 17,134 Second quarter ending net debt 17,830 Third quarter ending net debt 17,150 Year-end ending net debt 16,666 Five-quarter average net debt 17,265 Debt-to-adjusted EBITDA ratio 2.1x Operating Cash Flow Capital Expenditures Free Cash Flow Linde (as reported) 3,763 (1,949) 1,814 Praxair (as reported) 2,773 (1,465) 1,308 US GAAP adjustment* (384) - (384) Total 6,152 (3,414) 2,738

Important Information to Investors and Security Holders 22 Additional Information and Where to Find It

In connection with the proposed business combination between Praxair, Inc. (“Praxair”) and Linde AG (“Linde”), Linde plc has filed a Registration Statement on Form S-4 (which Registration Statement was declared effective on August 14, 2017) with the U.S. Securities and Exchange Commission (“SEC”) that includes (1) a proxy statement of Praxair that also constitutes a prospectus for Linde plc and (2) an offering prospectus of Linde plc to be used in connection with Linde plc’s offer to acquire Lindeshares held by U.S. holders. Praxair has mailed the proxy statement/prospectus to its stockholders in connection with the vote to approve the merger of Praxair and an indirect wholly-owned subsidiary of Linde plc, and Linde plc has distributed the offering prospectus to Linde shareholders in the United States in connection with Linde plc’s offer to acquire all of the outstanding shares of Linde. Linde plc has also filed an offer document with the German Federal Financial Supervisory Authority (Bundesanstalt fuer Finanzdienstleistungsaufsicht) (“BaFin”) which was approved for publication by BaFin on August 14, 2017 and published by Linde plc on August 15, 2017. The consummation of the proposed business combination is subject to regulatory approvals and other customary closing conditions. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND THE OFFER DOCUMENT REGARDING THE PROPOSED BUSINESS COMBINATION TRANSACTION AND OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the proxy statement/prospectus and other related documents filed by Praxair, Linde and Linde plc with the SEC on the SEC’s Web site at www.sec.gov. The proxy statement/prospectus and other documents relating thereto may also be obtained for free by accessing Praxair’s Web site at www.praxair.com. The offer document is available for free at Linde plc’s Web site at www.lindepraxairmerger.com. Furthermore, the offer document is available at BaFin’s Web site for free at www.bafin.de. You may also obtain a copy of the offer document from Deutsche Bank Aktiengesellschaft, Taunusanlage 12, 60325 Frankfurt am Main, Germany for distribution free of charge (also available from Deutsche Bank Aktiengesellschaft via e-mail to dct.tender-offers@db.com or by telefax to +49 69 910 38794). This document is neither an offer to purchase nor a solicitation of an offer to sell shares of Linde plc, Praxair or Linde. The final terms and further provisions regarding the public offer are disclosed in the offer document and in documents that will be filed with the SEC. No money, securities or other consideration is being solicited, and, if sent in response to the information contained herein, will not be accepted. The information contained herein should not be considered as a recommendation that any person should subscribe for or purchase any securities. No offering of securities shall be made except by means of a prospectus meeting the requirements of the U.S. Securities Act of 1933, as amended, and applicable European and German regulations. The distribution of this document may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein come should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Subject to the exceptions described in the offer document and to any exceptions potentially granted by the respective regulatory authorities, no offering of securities will be made directly or indirectly in any jurisdiction where to do so would be a violation of the respective national laws. Participants in Solicitation Praxair, Linde, Linde plc and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Praxair’s stockholders in respect of the proposed business combination. Information regarding the persons who are, under the rules of the SEC, participants in the solicitation of the stockholders of Praxair in connection with the proposed transaction, including a description of their direct or indirect interests, by security holdings or otherwise, are set forth in the proxy statement/prospectus filed with the SEC. Information regarding the directors and executive officers of Praxair is contained in Praxair’s Annual Report on Form 10-K for the year ended December 31, 2016 and its Proxy Statement on Schedule 14A, dated March 15, 2017, which are filed with the SEC and can be obtained free of charge from the sources indicated above. Forward-looking Statements This communication includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on our beliefs and assumptions on the basis of factors currently known to us. These forward-looking statements are identified by terms and phrases such as: anticipate, believe, intend, estimate, expect, continue, should, could, may, plan, project, predict, will, potential, forecast, and similar expressions. These forward-looking statements include, but are not limited to, statements regarding benefits of the proposed business combination, integration plans and expected synergies, and anticipated future growth, financial and operating performance and results. Forward-looking statements involve risks and uncertainties that may cause actual results to be materially different from the results predicted or

expected. No assurance can be given that these forward-looking statements will prove accurate and correct, or that projected or anticipated future results will be achieved. Factors that could cause actual results to differ materially from those indicated in any forward-looking statement include, but are not limited to: the expected timing and likelihood of the completion of the contemplated business combination, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the contemplated business combination that could reduce anticipated benefits or cause the parties to abandon the transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination agreement; the ability to successfully complete the proposed business combination and the exchange offer; regulatory or other limitations imposed as a result of the proposed business combination; the success of the business following the proposed business combination; the ability to successfully integrate the Praxair and Linde businesses; the possibility that Praxair stockholders may not approve the business combination agreement or that the requisite number of Linde shares may not be tendered in the public offer; the risk that the parties may not be able to satisfy the conditions to closing of the proposed business combination in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the proposed business combination; the risk that the announcement or consummation of the proposed business combination could have adverse effects on the market price of Linde's or Praxair's common stock or the ability of Linde and Praxair to retain customers, retain or hire key personnel, maintain relationships with their respective suppliers and customers, and on their operating results and businesses generally; the risk that Linde plc may be unable to achieve expected synergies or that it may take longer or be more costly than expected to achieve those synergies; state, provincial, federal and foreign legislative and regulatory initiatives that affect cost and investment recovery, have an effect on rate structure, and affect the speed at and degree to which competition enters the industrial gas, engineering and healthcare industries; outcomes of litigation and regulatory investigations, proceedings or inquiries; the timing and extent of changes in commodity prices, interest rates and foreign currency exchange rates; general economic conditions, including the risk of a prolonged economic slowdown or decline, or the risk of delay in a recovery, which can affect the long-term demand for industrial gas, engineering and healthcare and related services; potential effects arising from terrorist attacks and any consequential or other hostilities; changes in environmental, safety and other laws and regulations; the development of alternative energy resources; results and costs of financing efforts, including the ability to obtain financing on favorable terms, which can be affected by various factors, including credit ratings and general market and economic conditions; increases in the cost of goods and services required to complete capital projects; the effects of accounting pronouncements issued periodically by accounting standard-setting bodies; conditions of the debt and capital markets; market acceptance of and continued demand for Linde's and Praxair's products and services; changes in tax laws, regulations or interpretations that could increase Praxair's, Linde's or Linde plc's consolidated tax liabilities; and such other factors as are set forth in Linde's annual and interim financial reports made publicly available and Praxair's and Linde plc's public filings made with the SEC from time to time, including but not limited to those described under the headings "Risk Factors" and "Forward-Looking Statements" in Praxair's Form 10-K for the fiscal year ended December 31, 2016, which are available via the SEC's Web site at www.sec.gov. The foregoing list of risk factors is not exhaustive. These risks, as well as other risks associated with the contemplated business combination, are more fully discussed in the proxy statement/prospectus and the offering prospectus included in the Registration Statement on Form S-4 filed with the SEC and in the offering document and/or any prospectuses or supplements to be filed with BaFin in connection with the contemplated business combination. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than Linde, Praxair or Linde plc has described. All such factors are difficult to predict and beyond our control. All forward-looking statements included in this document are based upon information available to Linde, Praxair and Linde plc on the date hereof, and each of Linde, Praxair and Linde plc disclaims and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Edgar Filing: PRAXAIR INC - Form 425

Linde Investor Contact Bernard Wang bernard.wang@linde.com+49 89 35757 1328 Praxair Investor Contact Juan Pelaez Juan_Pelaez@praxair.com+1 203 837 2213 www.lindepraxairmerger.com